Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | MC2R | Q01718 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8224313 | 0.93 | MGLL (0.42) | MGLLCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL4385982 | 0.90 | HCRTR1 (0.40) | MC2RMAPK10 | |
| SCHEMBL4388248 | 0.89 | KDM5A (0.41) | MGLLHSD11B1MAPK8MAPK10 | |
| SCHEMBL4389150 | 0.87 | HCRTR1 (0.42) | MGLLMC2RHSD11B1PARP1 | |
| SCHEMBL8224518 | 0.84 | CYP2C9 (0.42) | MGLLCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL4387380 | 0.83 | HCRTR1 (0.47) | — | |
| SCHEMBL4241934 | 0.82 | HCRTR1 (0.44) | MAPK10 | |
| SCHEMBL4241941 | 0.82 | HCRTR1 (0.44) | MAPK10 | |
| SCHEMBL4392235 | 0.81 | GFER (0.41) | — | |
| SCHEMBL4244110 | 0.81 | HSD11B1 (0.46) | MGLLHSD11B1MAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | MGLL 1527/4885MC2R 57/4885SLC6A2 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.